Highlighted transactions



Encore Vision, Inc.

Piper Jaffray served as exclusive financial advisor to Encore Vision, Inc. on its sale to Novartis AG.

Client Description

Encore Vision is a Fort Worth-based, privately held, clinical stage pharmaceutical company focused on developing therapeutics in ophthalmology. Encore Vision’s lead product candidate, EV06 ophthalmic solution (EV06), is a novel topical, Phase II-b ready therapy that targets presbyopia by restoring crystalline lens flexibility, thereby allowing the lens to focus on nearby objects.

Counterparty Description

Novartis AG is one of the largest healthcare and pharmaceutical companies in the world, with over $50 billion in revenues and a market capitalization in excess of $170 billion. Novartis operates through three segments: pharmaceuticals (patented prescription medicines), Alcon (eye care products) and Sandoz (generic prescription medicines). Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.